| Dr Dana Alan Campbell, MD | |
|
401 Corbett St Ste 250, Belleair, FL 33756-7310 | |
| (727) 734-2485 | |
| (888) 972-3760 |
| Full Name | Dr Dana Alan Campbell |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 37 Years |
| Location | 401 Corbett St Ste 250, Belleair, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902873623 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | ME93564 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Renviva Dialysis Center Of Clearwater, Llc | Clearwater, FL | Dialysis facility |
| Fkc - Belleair Dialysis Center | Clearwater, FL | Dialysis facility |
| Fresenius Kidney Care-dunedin | Dunedin, FL | Dialysis facility |
| Fmc - Belleair Home Therapies | Clearwater, FL | Dialysis facility |
| Morton Plant Hospital | Clearwater, FL | Hospital |
| Morton Plant Mease Healthcare Countryside | Safety harbor, FL | Hospital |
| Mease Dunedin Hospital | Dunedin, FL | Hospital |
| St Josephs Hospital | Tampa, FL | Hospital |
| Entity Name | Vidya Sagar Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477733566 PECOS PAC ID: 6901980101 Enrollment ID: O20080227000153 |
News Archive
X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.
An inexpensive, FDA-approved drug - cholestyramine - taken in conjunction with an antibiotic prevents the antibiotic from driving antimicrobial resistance, according to new research by scientists at Penn State and the University of Michigan. The team's findings appear today (Dec. 1) in the journal eLife.
Today at Jersey Shore University Medical Center, 66-year-old heart attack survivor Charles Theodora from Ocean Township became the first NY/NJ Metropolitan resident to be implanted with the experimental AngelMed Guardian cardiac monitor and alert system device that could alert him if a heart attack is imminent.
Results from a new study co-led by researchers at Dartmouth's Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer.
› Verified 4 days ago
| Entity Name | D A Campbell Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164766721 PECOS PAC ID: 1254583198 Enrollment ID: O20121128000722 |
News Archive
X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.
An inexpensive, FDA-approved drug - cholestyramine - taken in conjunction with an antibiotic prevents the antibiotic from driving antimicrobial resistance, according to new research by scientists at Penn State and the University of Michigan. The team's findings appear today (Dec. 1) in the journal eLife.
Today at Jersey Shore University Medical Center, 66-year-old heart attack survivor Charles Theodora from Ocean Township became the first NY/NJ Metropolitan resident to be implanted with the experimental AngelMed Guardian cardiac monitor and alert system device that could alert him if a heart attack is imminent.
Results from a new study co-led by researchers at Dartmouth's Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Dana Alan Campbell, MD 401 Corbett St Ste 250, Belleair, FL 33756-7310 Ph: (727) 734-2485 | Dr Dana Alan Campbell, MD 401 Corbett St Ste 250, Belleair, FL 33756-7310 Ph: (727) 734-2485 |
News Archive
X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.
An inexpensive, FDA-approved drug - cholestyramine - taken in conjunction with an antibiotic prevents the antibiotic from driving antimicrobial resistance, according to new research by scientists at Penn State and the University of Michigan. The team's findings appear today (Dec. 1) in the journal eLife.
Today at Jersey Shore University Medical Center, 66-year-old heart attack survivor Charles Theodora from Ocean Township became the first NY/NJ Metropolitan resident to be implanted with the experimental AngelMed Guardian cardiac monitor and alert system device that could alert him if a heart attack is imminent.
Results from a new study co-led by researchers at Dartmouth's Geisel School of Medicine and the Department of Surgery at Kuma Hospital in Kobe, Japan show that active surveillance can be successfully implemented as a viable treatment option for patients with low-risk thyroid cancer.
› Verified 4 days ago
Dr. Muhammad Zubair Saeed Malik, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 401 Corbett St Ste 250, Belleair, FL 33756 Phone: 407-255-1758 Fax: 888-315-6692 | |
Dr. Eric D Weston, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 401 Corbett St, Suite 350, Belleair, FL 33756 Phone: 727-298-0802 Fax: 727-298-0272 | |
Melina Trunghau Doan, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 401 Corbett St Ste 240, Belleair, FL 33756 Phone: 727-298-1721 Fax: 727-298-1723 |